Full-Time

Patient Access Liaison

Updated on 8/24/2026

Deadline 9/10/26
Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$158.4k - $222.3k/yr

Long Beach, CA, USA

In Person

Travel up to 50%, including occasional overnight and weekend commitments.

Bachelor's, Master's, PhD, Associate's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Microsoft Office
FDA Regulations
Nursing
CRM
HIPAA

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree; or a master's degree with the required patient services and/or access and reimbursement experience; or a bachelor's degree with the required experience; or an associate's degree with the required experience; or a high school diploma/GED with the required experience, depending on level.
  • For Level 6, a doctorate degree with 2 years of experience, a master's degree with 4 years of experience, or a bachelor's degree with 6 years of experience in patient services and/or access and reimbursement is required.
Responsibilities
  • Serve as a resource on patient access and reimbursement for infused and specialty therapies.
  • Assist patients, caregivers, and healthcare providers in navigating insurance benefits, prior authorization requirements, and reimbursement processes.
  • Support the identification and resolution of access challenges, including coverage questions, prior authorization barriers, and denied claims.
  • Provide education regarding coding and billing considerations relevant to therapy access.
  • Develop relationships with patients and caregivers through phone, virtual, and in-person engagement.
  • Secure written or electronic patient HIPAA authorization within the assigned geography.
  • Assess individual patient needs and provide education and resources that support access to therapy.
  • Educate patients on coverage considerations and the steps required to obtain prior authorization.
  • Provide information regarding co-pay assistance programs, national foundations, and free drug programs when appropriate.
  • Educate physician offices and sites of care on therapy coverage pathways and reimbursement processes.
  • Provide information regarding common prior authorization requirements, coding considerations, and billing practices.
  • Support healthcare providers and infusion centers in navigating reimbursement questions related to patient cases.
  • Investigate patient access challenges before and after infusion.
  • Support physician offices and sites of care in reviewing denied claims and identifying potential next steps.
  • Escalate complex or systemic reimbursement issues to appropriate internal stakeholders.
  • Partner with Market Access, Medical Affairs, Advocacy, Case Management, and Site of Care teams to support patient access initiatives.
  • Coordinate with internal and external partners to ensure appropriate resources are available to support patient access.
  • Share field insights regarding payer policies and reimbursement challenges.
  • Adhere to company policies, compliance guidance, and applicable federal, state, and local regulations.
  • Ensure activities align with HIPAA privacy requirements and internal compliance guidelines.
  • Report adverse events and product complaints through established pharmacovigilance processes.
  • Maintain accurate documentation of activities and interactions in Amgen's internal system.
Desired Qualifications
  • Experience supporting buy-and-bill or infused pharmaceutical therapies.
  • Rare disease or orphan drug experience.
  • A clinical background such as nursing or allied health.
  • Understanding of reimbursement processes, including prior authorization, appeals, and denied claims management.
  • Knowledge of HIPAA guidelines and FDA regulatory requirements.
  • Familiarity with internal and Office of Inspector General compliance guidelines.
  • Strong analytical and problem-solving skills.
  • Excellent written and verbal communication skills.
  • Ability to manage complex patient situations and resolve access barriers.
  • Experience working in cross-functional field teams.
  • Proficiency in Microsoft Office, customer relationship management systems, artificial intelligence, and relevant systems.
  • Access and reimbursement knowledge.
  • Knowledge of prior authorization processes, healthcare reimbursement systems, coding and billing, patient support programs, and compliance and privacy requirements.
  • Learning agility, decision quality, and stakeholder engagement.
  • Ability to respond rapidly to urgent access needs to prevent treatment delays or lapses.
  • Ability to operate effectively in matrix field environments.
  • Willingness to travel up to 50%, including occasional overnight and weekend commitments.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.